Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
Sarina A Piha-PaulChristine L HannChristopher A FrenchSophie CousinIrene BrañaPhillippe A CassierVictor MorenoJohann S de BonoSara Duckworth HarwardGeraldine Ferron-BradyOlena BarbashAnastasia WyceYuehui WuThierry HornerMeg AnnanNigel J ParrRabinder K PrinjhaChristopher L CarpenterJohn HiltonDavid S HongNaomi B HaasMark C MarkowskiArindam DharPeter J O'DwyerGeoffrey I ShapiroPublished in: JNCI cancer spectrum (2019)
Once-daily molibresib was tolerated at doses demonstrating target engagement. Preliminary data indicate proof-of-concept in NC.